Ocular Therapeutix
NASDAQ · OCUL·Bedford, MA·Small-cap·Phase 3
Late-stage ophthalmology company building sustained-release intravitreal therapies on the ELUTYX bioresorbable hydrogel platform. Lead program AXPAXLI (axitinib hydrogel) is in Phase 3 for wet AMD and non-proliferative diabetic retinopathy, with a TKI mechanism aimed at reducing the anti-VEGF injection burden.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Ocular Therapeutix Corporate Overview | Corporate overview | April 15, 2026 | 20 |